Clopidogrel: With or Without a Proton Pump Inhibitor?

Geriatric Nursing

Volumn 30, Issue 3, 2009, Pages 188-192

  Zarowitz, Barbara J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; PROTON PUMP INHIBITOR; TICLOPIDINE;

ARTICLE; DRUG INTERACTION; HUMAN;

DRUG INTERACTIONS; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 66449135111     PISSN: 01974572     EISSN: 15283984     Source Type: Journal    
DOI: 10.1016/j.gerinurse.2009.03.001     Document Type: Article

References (18)

1. Plavix® (clopidogrel bisulfate) Tablets Product Information. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Bridgewater, NJ 08807 (March 2008)
2. Clinical Pharmacology Online. Gold Standard, an Elsevier Company, Tampa, FL, 2009. Available at www.clinicalpharmacology.com. Cited March 21, 2009.
3. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 348 (1996) 1329-1339
4. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
5. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID Use. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118:1894-1909. Available at http://circ.ahajournals.org. Cited March 21, 2009.
6. Shi S., and Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64 (2008) 935-951
7. Aubert R.E., Epstein R.S., Teagarden J.R., et al. Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study. Circulation 118 suppl 2 (2008) abstract 3998
8. Gilard M., Arnaud B., Cornily J.C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol 51 (2008) 256-260
9. Simon T., Verstuyft C., Mary-Krause M., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Eng J Med 360 (2009) 411-413
10. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 44 (2006) 297-302
11. Desta Z., Zhao X., Shin J.G., and Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41 (2002) 913-958
12. Baldwin R.M., Ohlsson S., Pedersen R.S., et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 65 (2008) 767-774
13. Ishizawa Y., Yasui-Furukori N., Takahata T., et al. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet 44 (2005) 1179-1189
14. Hu X.P., Xu J.M., Hu Y.M., et al. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people. J Clin Pharm Ther 32 (2007) 517-524
15. Ko J.W., Sukhova N., Thacker D., et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Disposition 25 (1997) 853-862
16. Siller Matula J.M., Spiel M.O., Lang I.M., et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157 (2009) 148 e1-5
17. Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix) Food and Drug Administration, Center for Drug Evaluation and Research. Available at www.fda.gov/cder/drug/early_comm/clopidgrel_bisulfate.htm. Cited March 21, 2009.
18. Juurlink D.N., Gomes T., Lo D.T., et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Can Med Assoc J 180 (2009) 713-718